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Abstract
Objective:  Prostacyclin  (PGI2)  has  been  shown  to  inhibit  the  expression  of  pro-inﬂammatory
and pro-ﬁbrotic  mediators  in  pulmonary  ﬁbrosis.  In  this  study,  we  aimed  to  test  the  preventive
effects  of  intraperitoneally  administered  iloprost,  a  stable  PGI2  analog,  on  bleomycin-induced
pulmonary  ﬁbrosis  in  rats  and  to  compare  the  effects  of  iloprost  with  the  effects  of  methyl-
prednisolone,  a  traditional  therapy.
Methods: Rats  were  randomly  allocated  into  four  groups:  1.  Saline  alone  (n  =  6);  2.  Bleomycin  +
placebo (n  =  7);  3.  Bleomycin  +  methyl-prednisolone  (n  =  7);  4.  Bleomycin  +  iloprost  (n  =  7).
Fibrotic changes  in  the  lungs  were  demonstrated  by  analyzing  the  cellular  composition  of
bronchoalveolar  lavage  ﬂuid,  histological  evaluation  and  lung  hydroxyproline  content.
Results: Fibrosis  was  made  in  the  lungs  of  rats  by  bleomycin  experimentally.  Fibrosis  scores  in
the methyl-prednisolone  and  the  iloprost  groups  were  signiﬁcantly  lower  than  in  the  placebo
group (p  <  0.05).  Furthermore,  the  score  of  the  iloprost  group  was  signiﬁcantly  lower  than  the
score of  the  methyl-prednisolone  group.  The  hydroxyproline  content  was  signiﬁcantly  less  in
the methyl-prednisolone  and  the  iloprost  groups  (p  <  0.05).  In  the  placebo  group,  the  neutrophil
percentage  in  bronchoalveolar  lavage  was  signiﬁcantly  higher  than  in  the  other  groups,  whereas
the macrophage  percentage  in  placebo  group  was  signiﬁcantly  lower  (p  <  0.05).
Conclusion:  Iloprost  has  protective  effect  on  the  pulmonary  ﬁbrosis  induced  by  bleomycin  and
it may  be  more  effective  in  decreasing  ﬁbrotic  changes  than  methyl-prednisolone.
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Efeitos  do  iloprost  na  ﬁbrose  pulmonar  induzida  por  bleomicina  no  rato
em  comparac¸ão  com  metil-prednisolona
Resumo
Objetivo:  A  prostaciclina  (PGI2)  é  conhecida  por  inibir  a  expressão  de  mediadores  pró-
inﬂamatórios  e  pró-ﬁbróticos  na  ﬁbrose  pulmonar.  Neste  estudo,  procurou-se  testar  os  efeitos
preventivos  do  iloprost  administrado  por  via  intraperitoneal,  um  análogo  estável  do  PGI2,  na
ﬁbrose pulmonar  induzida  por  bleomicina  em  ratos  e  comparar  os  efeitos  do  iloprost  com  os
efeitos da  metil-prednisolona,  uma  terapia  tradicional.
Métodos: Os ratos  foram  divididos  aleatoriamente  em  quatro  grupos:  1.  Apenas  soro  ﬁsiológico
(n=6); 2.  Bleomicina  +  placebo  (n=7);  3.  Bleomicina  +  metil-prednisolona  (n=7);  4.  Bleomicina  +
iloprost (n=7).  Foram  demonstradas  alterac¸ões  ﬁbróticas  nos  pulmões  analisando  a  composic¸ão
celular do  líquido  de  lavagem  bronco-alveolar,  avaliac¸ão  histológica  e  conteúdo  de  hidroxipro-
lina pulmonar.
Resultados: Aparecimento  de  ﬁbrose  nos  pulmões  dos  ratos  tratados  com  bleomicina.  Os  resul-
tados dos  grupos  tratados  com  metil-prednisolona  e  iloprost  foram  signiﬁcativamente  inferiores
ao do  grupo  placebo  (p<0.05).  Além  disso,  o  resultado  do  grupo  de  iloprost  foi  signiﬁcativamente
inferior ao  resultado  do  grupo  de  metil-prednisolona.  O  teor  de  hidroxiprolina  foi  signiﬁcati-
vamente inferior  nos  grupos  de  metil-prednisolona  e  de  iloprost  (p  <0.05).  No  grupo  placebo,
a percentagem  de  neutróﬁlos  na  lavagem  bronco-alveolar  foi  signiﬁcativamente  mais  elevada
do que  nos  outros  grupos,  enquanto  que  a  percentagem  de  macrófagos  no  grupo  placebo  foi
signiﬁcativamente  inferior  (p  <0.05).
Conclusão:  O  Iloprost  tem  um  efeito  protetor  sobre  a  ﬁbrose  pulmonar  induzida  por  bleomicina
e pode  ser  mais  eﬁcaz  na  diminuic¸ão  de  alterac¸ões  ﬁbróticas  que  a  metil-prednisolona.
© 2011  Sociedade  Portuguesa  de  Pneumologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
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iIntroduction
Idiopathic  pulmonary  ﬁbrosis  (IPF)  is  a  chronic,  progressively
fatal  lung  disease  characterized  by  ﬁbroblast  proliferation
and  extracellular  matrix  remodeling.  Unfortunately,  despite
intensive  investigations,  the  current  pharmacologic  ther-
apy  of  IPF  is  limited  and  the  results  of  therapy  have  been
unsuccessful.1,2 Lung  transplantation  is  considered  as  the
only  solution  that  has  been  shown  to  prolong  survival;  how-
ever,  it  can  be  applied  to  limited  patient  groups.3
Animal  models  play  an  important  role  in  the  inves-
tigation  of  IPF.  Chronic  diseases,  such  as  IPF  are  more
difﬁcult  to  apply  to  a  model  because,  etiology  and  natu-
ral  history  of  IPF  are  unclear  and  there  is  no  known  single
trigger  able  to  induce  ‘‘IPF’’  in  animals.2 There  are  dif-
ferent  models  for  inducing  the  pulmonary  ﬁbrosis.  One  of
the  models  is  intratracheal  bleomycin  (BLM)  instillation.  BLM
is  a  chemotherapeutic  antibiotic,  and  pulmonary  ﬁbrosis  is
one  of  the  major  adverse  effects  of  this  agent  in  human
cancer  therapy.  Nowadays,  the  standard  agent  for  inducing
the  experimental  pulmonary  ﬁbrosis  is  BLM.  BLM-induced
pulmonary  damage  of  animal  lungs  reﬂects  histological
and  biochemical  characteristics  of  ﬁbrosis  well.  Meanwhile,
there  is  an  evidence  that  bioactive  metabolites  of  arachi-
donic  acid  may  regulate  the  ﬁbroproliferative  response  in
lung  ﬁbrosis.4,5 Deletion  of  5-lypoxygenase  (5-LO)  leading
to  a  deﬁciency  in  sulphidopeptide-leukotriene  production
ameliorated  bleomycin-induced  ﬁbrosis  in  mice.6 Further-
more,  antagonizing  leukotriene  (LT)  B4  receptor  (LT  B4  is  a
metabolite  synthesized  by  5-LO)  attenuated  the  lung  ﬁbro-
sis  induced  by  BLM  in  mice  by  suppressing  the  production
u
a
mf inﬂammatory  and  ﬁbrotic  cytokines  and  by  promoting
he  antiﬁbrotic  cytokine.7 In  contrast  to  LTB4,  prostanoids,
hich  are  metabolites  of  arachidonic  acid  are  important
egulators  of  pulmonary  homeostasis.  Prostacyclin  inhibits
broblast  proliferation  and  collagen  synthesis.8
PGI2,  known  as  prostacyclin,  is  produced  by  the  action
f  cyclooxygenase  (COX)-2,  as  an  antiproliferative  molecule
n  the  setting  of  BLM-induced  pulmonary  ﬁbrosis.9 Lov-
ren  et  al.  reported  that  mice  lacking  COX-2  derived  PGI2
ere  susceptible  to  developing  severe  pulmonary  ﬁbrosis
n  response  to  BLM.10 In  that  case,  it  can  be  said  that
GI2  may  inhibit  the  development  of  pulmonary  ﬁbrosis.
herefore,  Zhu  et  al.  demonstrated  that  iloprost,  a  sta-
le  PGI2,  prevents  BLM-induced  pulmonary  ﬁbrosis  in  a
ouse  model  and  these  authors  reported  that  prostacyclin
ay  represent  a  novel  pharmacological  agent  for  treating
ulmonary  ﬁbrosis.11 However,  Dactor  et  al.  reported  that
rostanoids  protected  against  lung  ﬁbrosis  when  prostanoid
as  administered  before  bleomycin  challenge  but  had
o  therapeutic  effect  when  administered  after  bleomycin
hallenge.12
Corticosteroids  suppress  neutrophil  and  lymphocyte
igration  into  the  lung,  decrease  the  level  of  immune  com-
lexes,  and  alter  alveolar  macrophages  function  but  it  is
nclear  that  there  is  any  survival  advantage  or  prevention
f  ﬁbrosis  in  patients  treated  with  corticosteroids  alone  or
n  combination  with  other  agents.3This  study  aimed  to  investigate  the  effects  of  PGI2  by
sing  iloprost  on  lung  ﬁbrosis  induced  by  BLM  exposure  in
 rat  model  and  to  compare  the  effects  of  iloprost  with
ethyl-prednisolone,  a  traditional  therapy.
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aterial and methods
xperimental  animals
n  this  study,  27  male  Wistar  albino  rats,  12-week  old,
eighing  200--250  g  were  purchased  from  Inonu  Univer-
ity  Experiment  Animals  Production  and  Research  Center.
ll  experiments  were  approved  by  the  institutional  com-
ittee  of  animal  care.  The  rats  were  randomly  allocated
nto  4  groups.  1.  Saline  alone  (control  group)  (n  = 6);
.  BLM  +  placebo  (n  =  7);  3.  BLM  +  methyl-prednisolone
n  =  7);  4.  BLM  +  iloprost  (n  =  7).
LM-induced  lung  ﬁbrosis
he  rats  were  anesthetized  with  50  mg/kg  ketamin  and
 mg/kg  xyalazine  intraperitoneally,  followed  by  a  single
ntratracheal  injection  of  BLM  hydrochloride  (2.5  mg/kg
ody  weight  in  0.25  ml  phosphate  buffered  saline  (PBS),
ippon  Kayaku,  Japan)  in  50  ml  of  sterile  saline.  Control
ats  were  injected  the  same  volume  of  intratracheal  saline
nstead  of  BLM.  All  the  rats  were  killed  14  days  after  the
ntratracheal  injection  of  bleomycin  or  PBS.
xperimental  groups
n  control  and  placebo  groups,  injection  of  0.1  ml  PBS  started
ntraperitoneally  two  days  before  the  intratracheal  injection
f  PBS  or  BLM.  This  solution  was  administered  intraperi-
oneally  for  16  days  in  two  groups.  Steroid  treated  rats  were
njected  5  mg/kg/day  methyl-prednisolone  (Mustafa  Nevzat
td.,  Istanbul,  Turkey)  intraperitoneally  two  days  before  the
LM  injection  and  drug  was  administered  in  the  same  dose
or  16  days.  In  the  iloprost  group,  iloprost  (200  g/kg  Scher-
ng,  Berlimed,  Spain)  was  dissolved  in  500  l  of  PBS.  The  dose
evels  were  based  on  a  previous  study  in  the  literature.11
irst  doses  of  iloprost  were  administered  intraperitoneally
wo  days  before  the  BLM  injection.  Iloprost  was  adminis-
ered  intraperitoneally  for  16  days.  Treatment  procedures
ere  based  on  previous  drug  studies  in  bleomycin-induced
ung  ﬁbrosis  in  rats.2,11,13
ronchoalveolar  lavage
n  day  14  after  the  BLM  injection,  rats  were  euthanized
ith  xylazine  (5  mg/kg)  and  ketamine  (50  mg/kg)  intraperi-
oneally.  The  trachea  was  cannulated  by  using  a  blunt  needle
ttached  to  a  syringe.  Bronchoalveolar  lavage  (BAL)  was  per-
ormed  four  times  with  0.8  ml  of  PBS.  Cell  suspensions  were
oncentrated  by  low  speed  centrifugation.  The  supernatant
f  BAL  ﬂuid  was  collected  and  kept  at  −70 ◦C  until  used.
he  supernatant  was  used  for  the  measurement  of  total
ell  counts.  Total  cells  were  counted  on  a  hemocytome-
er  and  differential  cell  (alveolar  macrophages,  neutrophils,
ymphocytes  and  eosinophils),  counts  were  estimated  from
ystospine  preparations  by  counting  300  cells  stained  with
ay-Grünwald-Giemsa.
m
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ung  histopathology
fter  BAL,  the  left  lungs  of  scariﬁced  rats  were  removed,
xed  in  a  buffered  10%  formalin  solution  for  24  h,  embedded
n  paraﬁn  and  sectioned  at  5  m  thickness.  Ten  consecu-
ive  longitudinal  sections  of  the  lungs  were  stained  with
ematoxylin  &  eosin  (HE)  and  were  examined  for  pul-
onary  ﬁbrosis.  For  histopathological  scoring  of  pulmonary
brosis,  each  successive  ﬁeld  was  assessed  using  the  semi-
uantitative  grading  system  described  by  Ashcroft  et  al.14
he  entire  lung  section  was  reviewed  at  a magniﬁcation
f  100×. Thirty  to  thirty  ﬁve  ﬁelds  in  each  section  were
nalyzed  and  a  score  ranging  from  0  (normal  lung)  to
 (total  ﬁbrosis)  was  assigned.  The  mean  score  of  all  ﬁelds
as  taken  as  the  ﬁbrosis  score  of  that  lung  section.  Crite-
ia  for  grading  pulmonary  ﬁbrosis  were  as  follows.  Grade
 =  normal  lung;  Grade  1  =  minimal  ﬁbrous  thickening  of  alve-
lar  or  bronchial  walls;  Grade  2--3  =  moderate  thickening  of
alls  without  obvious  damage  to  lung  architecture;  Grade
--5  =  increased  ﬁbrosis  with  deﬁnite  damage  to  lung  archi-
ecture  and  formation  of  ﬁbrous  bands  or  small  ﬁbrous  mass;
rade  6--7  =  severe  distortion  of  structure  and  large  ﬁbrous
reas;  Grade  8  =  total  ﬁbrotic  obliteration  of  the  ﬁeld.  The
rading  was  independently  performed  for  each  rat  in  a  blind
anner  by  two  pathologists.
ydroxyproline  assay
fter  BAL,  the  right  lungs  were  used  for  hydroxyproline
ontent  as  an  index  of  collagen  accumulation.  Lungs  were
omogenized  in  1  ml  of  PBS,  and  hydrolyzed  by  the  addition
f  1  ml  of  12  N  HCL  at  120 ◦C  for  16  h  and  dissolved  in  2  ml
eionized  water.  Samples  were  incubated  with  Chloramine  T
olution  for  20  min  at  room  temperature,  and  with  Ehrlich’s
olution  at  65 ◦C  for  15  min.  The  absorbance  of  the  Wnal
eaction  solutions  at  550  nm  were  measured  and  amount  of
ydroxyproline  was  obtained  as  microgram.15
tatistical  analysis
tatistics  package  program  (SPSS  11.0  for  Windows;  SPSS
nc.,  Chicago,  Illinois,  USA)  was  used  for  statistical  analy-
is.  Data  were  expressed  as  mean  ±  S.E.M.  Comparison  was
ade  by  one-way  ANOVA  followed  by  appropriate  post  hoc
est  including  multiple  comparison  test  (least  signiﬁcant  dif-
erence).  P  value  less  than  0.05  was  considered  statistically
igniﬁcant.
esults
nﬂammatory  cells  in  airways
LM  +  placebo  administration  caused  a  signiﬁcant  increase
n  the  percentage  of  the  neutrophils  in  BAL  ﬂuid
21.1  ±  2.7,  p  <  0.05)  (Table  1).  The  percentage  of  alveolar
acrophages  in  BLM  +  placebo  group  was  signiﬁcantly  lower
76.7  ±  2.3,  p  <  0.05).  In  rats  treated  with  iloprost  or  methyl-
rednisolone,  the  percentages  of  the  neutrophil  and  alveolar
acrophages  remained  similar  to  the  levels  of  control  rats.
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Table  1  Effects  of  iloprost  and  methyl-prednisolone  on  bleomycin-induced  changes  in  inﬂammatory  cells  in  BAL  ﬂuid.
Control
(n  =  6)
BLM  +  placebo
(n =  7)
BLM  +  methyl-prednisolone
(n =  7)
BLM  +  iloprost
(n  =  7)
Macrophages  91.6  ±  0.6  76.7  ±  2.3* 91.5  ±  1.8  91.8  ±  2.0
Neutrophils 6.6  ±  0.5  21.1  ±  2.7* 5.8  ±  1.7  5.3  ±  1.9
Lymphocytes 1.6  ±  0.5  2.0  ±  0.5  2.4  ±  0.3  2.8  ±  1.1
Eosinophils 0.0  ±  0.0  0.1  ±  0.1  0.1  ±  0.1  0.0  ±  0.0
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pData presented as mean ± SEM of groups.
* The percentages of macrophages and neutrophils BAL ﬂuid we
There  were  no  signiﬁcant  differences  in  the  percentages  of
lymphocytes  and  eosinophils  among  the  four  groups.
Grades  of  lung  ﬁbrosis  and  hydroxyproline
contents in  dried  lung  tissue
In  the  BLM  +  placebo,  BLM  administration  produced  a
signiﬁcant  rise  in  lung  tissue  hyroxyproline  content
(5.65  ±  0.78  g,  p  <  0.05)  as  compared  to  those  of  the
control  group  (3.37  ±  0.51  g).  The  hydroxyproline  content
was  signiﬁcantly  lower  in  BLM  +  methyl-prednisolone
(4.72  ±  0.25  g)  and  BLM  +  iloprost  (4.90  ±  0.39  g)  groups
(p  <  0.05)  (Fig.  1).  There  was  no  signiﬁcant  difference  in
lung  hyroxyproline  content  between  BLM  +  iloprost  and
BLM  +  methyl-prednisolone  groups.
Semiquantitative  assessment  of  the  lung  tissue  section
from  the  control  group  (with  no  treatment)  revealed  a
normal  alveolar  structure  (Fig.  2A).  Fourteen  days  after
BLM  injection,  rats  administered  BLM  +  placebo  had  more
severe  and  extensive  ﬁbrosis  (Fig.  2B).  Alveolar  walls  of
these  rats  were  thickened  and  the  air  spaces  were  col-
lapsed.  Pulmonary  ﬁbrosis  was  less  severe  in  the  iloprost  and
methyl-prednisolone  groups  (Fig.  2C  and  D).  Ashcroft  score
demonstrated  that  the  degrees  of  pulmonary  ﬁbrosis  in  the
BLM  +  methyl-prednisolone  (2.57  ±  0.94)  and  BLM  +  iloprost
groups  (2.29  ±  0.68)  were  signiﬁcantly  lower  than  those  of
the  BLM  +  placebo  groups  (4.86  ±  0.93)  (p  <  0.05)  (Fig.  3).
7
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Figure  1  The  contents  of  hydroxyproline  in  the  groups  of  con-
trol, BLM  +  placebo,  BLM  +  methyl-prednisolone,  BLM  +  iloprost.
a The  content  of  hydroxyproline  in  the  BLM  +  placebo
was signiﬁcantly  higher  than  the  control  group  (p  <  0.05).
b The  hydroxyproline  contents  in  the  BLM  +  methyl-prednisolone
and BLM  +  iloprost  groups  were  signiﬁcantly  lower  than  the
BLM +  placebo  groups  (p  <  0.05).
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bniﬁcantly low in BLM + placebo group (p < 0.05).
n  the  rats  treated  with  iloprost,  ﬁbrosis  score  was  signi-
cantly  lower  than  those  of  the  methyl-prednisolone  group
p  <  0.05).
iscussion
e  assessed  the  effects  of  intraperitoneal  administration
f  iloprost,  a  PGI2  analog,  on  BLM-induced  pulmonary
brosis  and  compared  the  effects  of  iloprost  with  methyl-
rednisolone.  Iloprost  reduced  BLM-induced  lung  ﬁbrosis
s  shown  by  assessment  of  semiquantitative  morpho-
ogical  indices  of  ﬁbrosis  and  hydroxyproline  content.
ibrosis  score  in  iloprost  group  was  signiﬁcantly  lower
han  in  methyl-prednisolone  group.  Iloprost  and  methyl-
rednisolone  signiﬁcantly  attenuated  lung  inﬁltration  by
eutrophils.  To  the  best  of  our  knowledge,  this  is  the  sec-
nd  study  of  an  intraperitoneal  administration  of  iloprost  in
brosis  induced  by  BLM  in  rats.  The  study  of  Zhu  et  al.  is  the
rst  report  of  an  intraperitoenal  application  of  iloprost.11
owever,  our  study  is  the  ﬁrst  report  to  compare  the  pre-
entive  effects  of  iloprost  with  methyl-prednisolone  on
ulmonary  ﬁbrosis.
Hallmarks  of  pulmonary  ﬁbrosis  include  subepithelial
broblastic  foci  and  excessive  deposition  of  collagen  and
xtracellular  matrix.  Lung  ﬁbroblasts  play  an  important  role
n  the  development  of  lung  ﬁbrosis.16 A  number  of  stud-
es  have  shown  that  prostanoids  may  play  a  role  in  limiting
brotic  responses  in  the  lungs.5,8--11 Prostanoids  are  capable
f  inhibiting  ﬁbroblast  migration,  proliferation,  and  colla-
en  synthesis.  Patients  with  IPF,  have  been  seen  with  a
ecrease  of  prostacyclin  production  from  lung  ﬁbroblasts.17
rostacyclin  syntase  expression  has  been  demonstrated  on
neumocytes,  ﬁbroblasts  and  endothelial  cells  in  the  healthy
ungs.  However,  this  expression  did  not  continue  to  increase
fter  induction  of  ﬁbrosis  with  BLM.10 The  treatment  of  rats
ith  prostacyclin  provided  protection  against  BLM-induced
brosis.  Our  data  showed  that  ﬁbrosis  score  and  hyrox-
proline  levels  decreased  in  rats  treated  with  iloprost  and
ethyl-prednisolone  groups.
This  point  implies  that  neutrophils  were  markedly  aug-
ented  in  lungs  of  rats  exposed  to  BLM  +  placebo  and
he  augmentation  of  neutrophils  into  the  lung  was  inhib-
ted  by  BLM  +  iloprost  and  BLM  +  methyl-prednisolone.  In
ats  treated  with  iloprost  and  methyl-prednisolone,  alveo-
ar  macrophages  remained  similar  to  the  levels  of  control
ats  whereas  alveolar  macrophages  in  BLM  +  placebo  group
ere  signiﬁcantly  lower.  Zhu  et  al.  showed  that  the  num-
er  of  inﬂammatory  cells  and  lymphocytes  accumulated  in
276  Z.A.  Aytemur  et  al.
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the  therapeutic  effects  in  severe  pulmonary  hypertension
secondary  to  pulmonary  ﬁbrosis.24,25 However,  there  is  no
human  study  in  English  literature  which  compares  the
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Figure  3  Fibrosis  scores  of  the  control,  BLM  +  placebo,
BLM +  methyl-prednisolone  and  BLM  +  iloprost  groups. a Ashcroft
score in  the  BLM  +  placebo  was  signiﬁcantly  higher  than  the
control  group  (p  <  0.05). b Ashcroft  score  in  the  BLM  +  methyl-igure  2  Histological  H  &  E  stained  sections  (200×)  repr
LM +  methyl-prednisolone  (D).
ungs  was  signiﬁcantly  higher  in  the  BLM  (no  iloprost)  group
han  those  treated  with  iloprost.  However,  there  was  no
igniﬁcant  difference  in  the  number  of  macrophages  and
eutrophils  in  BAL  ﬂuid  between  the  BLM  (no  iloprost)  and
he  BLM  +  iloprost  groups.11 These  divergent  results  may  be
ue  to  differences  in  study  protocol,  since  Zhu  et  al.  only
dministered  iloprost  10--15  min  prior  to  injection  of  BLM.
leomycin  increases  both  neutrophils  and  lymphocytes  in
he  lungs.  However,  in  our  study,  lymphocytes  did  not  signi-
cantly  accumulate  in  the  lungs  in  the  BLM  +  placebo  group.
n  rats  treated  with  iloprost  and  methyl-prednisolone,  lym-
hocytes  remained  similar  to  the  levels  of  BLM  +  placebo
roup.
During  the  last  50  years,  corticosteroid  use  has  evolved
nto  accepted  practice  in  the  treatment  of  IPF  despite  the
act  that  no  prospective  randomised  placebo-controlled  trial
as  ever  been  performed.3 Transient  clinical  response  was
ound  in  a  small  minority  of  patients  with  no  survival  beneﬁt
ompared  to  untreated  patients  in  some  studies.17--21 There
as  been  a  small  but  statistically  signiﬁcant  reduction  in
he  overall  use  of  corticosteroids  as  classic  treatment  since
he  publication  of  treatment  guidelines  in  recent  years.22
icheldi  et  al.,  carried  out  a  systematic  review  of  the  efﬁ-
acy  of  corticosteroids  in  the  treatment  of  IPF  reporting  that
o  randomized  controlled  trial  or  clinical  control  trials  in
hich  corticosteroid  treatment  was  compared  to  placebo
ere  available.  According  to  this  review,  results  did  not  sup-
ort  the  efﬁcacy  of  corticosteroid  in  the  treatment  of  IPF.23
p
g
w
Btative  of  control  (A),  BLM  +  placebo  (B),  BLM  +  iloprost  (C),
he  development  of  new  IPF  pathogenetic  paradigms  has
riven  research  into  new  therapeutic  strategies.24 In  litera-
ure,  there  are  some  human  studies  which  have  evaluatedrednisolone  was  signiﬁcantly  lower  than  the  BLM  +  placebo
roups  (p  <  0.05). c Ashcroft  score  in  the  BLM  +  iloprost  group
as signiﬁcantly  lower  than  the  BLM  +  methyl-prednisolone  and
LM  +  placebo  groups  (p  <  0.05).
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2Effects  of  iloprost  on  bleomycin-induced  pulmonary  ﬁbrosis  
therapeutic  effects  and  superiority  of  prostacyclin  analogs
with  corticosteroids  in  patients  with  IPF.  Animal  studies
show  that  prostacyclin  may  have  an  important  protec-
tive  role  in  ﬁbrotic  disease5,10,11 but  in  these  studies,  the
effects  of  prostacyclin  analogs  were  not  compared  with
traditional  therapies  such  as  corticosteroids.  In  the  study
of  Zhu  et  al.,  iloprost  was  given  10--15  min  prior  to  intra-
tracheal  BLM.  The  results  of  this  study  indicated  that
iloprost  could  be  preventive,  but  possibly  not  therapeutic
for  ﬁbrosis.11 The  authors  recommended  additional  studies
to  evaluate  both  the  reversal  effect  of  iloprost  in  a  time-  and
dose-dependent  fashion  and  whether  long-term  treatment
with  iloprost  would  be  beneﬁcial  for  patients  with  ﬁbrotic
lung  diseases.  In  the  study  of  Dactor  et  al.,  mice  were
administered  a  single  dose  of  bleomycin  via  oropharyngeal
aspiration.  Prostaglandin  E2  and  iloprost  were  administered
7  days  before  or  14  days  after  bleomycin  challenge.
When  administered  7  days  before  bleomycin  challenge,
prostaglandin  E2  protected  against  lung  ﬁbrosis.  However,
this  agent  had  no  therapeutic  effect  on  lung  ﬁbrosis  when
administered  14  days  after  bleomycin.12 In  our  study,  ﬁrst
doses  of  iloprost  were  administered  two  days  before  the
BLM  injection  and  it  was  continued  intraperitoneally  at  the
same  doses  for  16  days.  Intraperitoneal  administration  of
iloprost  attenuated  the  development  of  BLM-induced  pul-
monary  ﬁbrosis  and  iloprost  signiﬁcantly  improved  ﬁbrotic
process  in  comparison  to  methyl-prednisolone.
In  this  present  study,  we  did  not  compare  groups  accord-
ing  to  survival  and  mortality  which  was  expected  up  to  the
time  of  evaluation.  No  side-effects  related  to  iloprost  ther-
apy  were  observed.
In  conclusion,  our  ﬁndings  provide  evidence  of  the  ben-
eﬁcial  effects  of  iloprost  in  decreasing  pulmonary  ﬁbrosis
induced  by  BLM,  namely  by  decreased  inﬂammation,  lung
damage  and  ﬁbrogenic  activity  in  lung  tissue.
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